Current maintenance or controller treatments for COPD include tiotropoium, LAMA, LABA, LABA + ICS, LAMA + LABA, roflumilast, theophylline, and 'triple therapy' combining LAMA + LABA + ICS.

You have full access to this article via your institution. Available treatments for COPD are mainly palliative, and there are no therapies available that halt the decline in lung function or the ...

Further, if initial pharmacotherapy with LABA or LAMA after a COPD ... 1,8 Among treatment-related factors for nonadherence is the diversity of COPD pharmacotherapies and devices.

In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA) experienced superior improvements in lung ...

The other single-inhaler on the market for COPD triple therapy, fluticasone-umeclidinium ... powder inhaler over a metered-dose inhaler of LABA-LAMA-inhaled corticosteroid in a single inhaler ...

Corticosteroid + long-acting beta-2 agonist (LABA ... asthma therapy. If insufficient response after 2wks, use next higher strength. Max 1 inh of 500/50 twice daily. COPD: 1 inh of 250/50 ...

The Spanish COPD guidelines recommend treatment of the mixed COPD ... acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'.

In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA) experienced superior improvements in lung ...